Status:
UNKNOWN
Plasma Purification and Chronic Hepatitis B
Lead Sponsor:
Shanghai Pudong Hospital
Conditions:
Chronic Hepatitis b
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
To compare the efficacy of nucleoside analogues （HA） alone and plasma purification +HA in reducing HBV viral load.
Detailed Description
Chronic hepatitis B (CHB) is a major disease harmful to human health and an important cause of liver cirrhosis and liver cancer. Hepatitis B virus (HBV) cccDNA exists for a long time in the liver of i...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Chronic hepatitis B Disease
- hepatitis B virus HBeAg is positive
- hepatitis B virus HBV-DNA virus load is more than 100000cps/ml
Exclusion
- Hypotension
- Cardiopulmonary insufficiency
- Coagulation disorders
- Heparin allergy
Key Trial Info
Start Date :
March 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT04518553
Start Date
March 23 2021
End Date
September 30 2023
Last Update
March 17 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.